6,762 reports of this reaction
2.4% of all TIOTROPIUM BROMIDE reports
#7 most reported adverse reaction
WHEEZING is the #7 most commonly reported adverse reaction for TIOTROPIUM BROMIDE, manufactured by Boehringer Ingelheim Pharmaceuticals, Inc.. There are 6,762 FDA adverse event reports linking TIOTROPIUM BROMIDE to WHEEZING. This represents approximately 2.4% of all 284,745 adverse event reports for this drug.
TIOTROPIUM BROMIDE has an overall safety score of 78 out of 100. Patients taking TIOTROPIUM BROMIDE who experience wheezing should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
WHEEZING is a less commonly reported adverse event for TIOTROPIUM BROMIDE, but still significant enough to appear in the safety profile.
In addition to wheezing, the following adverse reactions have been reported for TIOTROPIUM BROMIDE:
The following drugs have also been linked to wheezing in FDA adverse event reports:
WHEEZING has been reported as an adverse event in 6,762 FDA reports for TIOTROPIUM BROMIDE. This does not prove causation, but indicates an association observed in post-market surveillance data.
WHEEZING accounts for approximately 2.4% of all adverse event reports for TIOTROPIUM BROMIDE, making it a notable side effect.
If you experience wheezing while taking TIOTROPIUM BROMIDE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.